Full Text View
Tabular View
No Study Results Posted
Related Studies
Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
This study is ongoing, but not recruiting participants.
Study NCT00846131   Information provided by Northwestern University

First Received on February 16, 2009.   Last Updated on April 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatocellular Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Hepatocellular
More general conditions related to this trial
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Sorafenib
Yttrium-90 (Y-90)
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Northwestern University
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services